ReNeuron Group plc - Notification of Allowance granted for US Patent
ReNeuron Group plc
("ReNeuron" or the "Company")
Notification of Allowance granted for US patent
ReNeuron Group plc (AIM: RENE), a
This important allowed patent protects both the composition of ReNeuron's hRPC cell-based therapeutic candidate and its method of use. As such, it constitutes a principal layer of intellectual property pertaining to the Company's retinal disease programme.
This notification of allowance in the US follows the previously announced grant of a US patent in
These recent patent grants add further intellectual property protection to the hRPC technology which already has patent protection in a number of other major territories including
The hRPC therapeutic candidate is currently undergoing Phase 2a clinical evaluation for the treatment of the inherited blindness-causing disorder retinitis pigmentosa (RP). This programme has been granted Orphan Drug Designation in both
Commenting on the notification of allowance,
"We are delighted to have received this latest US notice of allowance to add to ReNeuron's extensive patent estate of over 250 patents across 29 patent families encompassing all of its technologies and therapeutic candidates. This patent, together with the earlier patent granted in July, adds significant value to our hRPC patent estate, supporting our aim to secure future high value out-licensing deals for our retinal disease programme."
+44 (0) 20 3819 8400
Olav Hellebø, Chief Executive Officer
Michael Hunt, Chief Financial Officer
Buchanan (Media/Investor Relations)
+44 (0) 20 7466 5000
Mark Court, Sophie Wills, Tilly Abraham
Stifel Nicolaus Europe Limited (NOMAD and Joint Broker)
Ben Maddison, Stewart Wallace
+44 (0) 20 7710 7600
N+1 Singer (Joint Broker)
Aubrey Powell, James Moat, Tom Salvesen
+44 (0) 20 7496 3000
ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs. The Company's lead cell therapy candidate is in clinical development for the blindness-causing disease, retinitis pigmentosa.
ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that treat diseases of the brain. The Company also has the ability through its conditionally immortalised induced pluripotent stem cell (iPSC) platform to make any tissue cells of choice; in-house programmes are focused on treatments for blood cancers and diabetes.
ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com
Quick facts: ReNeuron Group PLC
Market Cap: -
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE